Evidence map›Paper›PMID 37881504›Full record

ArticleVaccine insights2023

Non-mucosal vaccination strategies to enhance mucosal immunity.

Lisa A Morici, James B McLachlan

Open access · greenAbstract read
In one paragraph

Article in Vaccine insights, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Lisa A MoriciTulane University School of Medicine, Department of Microbiology and Immunology, 1430 Tulane Avenue, New Orleans, LA, USA.
James B McLachlanTulane University School of Medicine, Department of Microbiology and Immunology, 1430 Tulane Avenue, New Orleans, LA, USA.
Tulane University · US

Funding

Using parenteral combination adjuvants to induce pan-mucosal cellular and humoral immunityR01AI166756 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI MCLACHLAN, JAMES B, MORICI, LISA A · 2022 to 2025
$3.3M
NIAID NIH HHS R01 AI166756
6 · The paper itself

Abstract

The SARS-CoV-2 pandemic has highlighted the need for improved vaccines that can elicit long-lasting mucosal immunity. Although mucosal delivery of vaccines represents a plausible method to enhance mucosal immunity, recent studies utilizing intradermal vaccine delivery or incorporation of unique adjuvants suggest that mucosal immunity may be achieved by vaccination via non-mucosal routes. In this expert insight, we highlight emerging evidence from pre-clinical studies that warrant further mechanistic investigation to improve next-generation vaccines against mucosal pathogens, especially those with pandemic potential.

Identifiers

PMID37881504
PMCPMC10599649
OpenAlexW4385668053

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.